Successes and Challenges on the Road to Cure Hepatitis C

Stacy M. Horner; Susanna Naggie

doi:10.1371/journal.ppat.1004854

Loading metrics

Open Access

Pearls provide concise, practical and educational insights into topics that span the pathogens field.

See all article types »

Successes and Challenges on the Road to Cure Hepatitis C

Stacy M. Horner ,

Contributed equally to this work with: Stacy M. Horner, Susanna Naggie

Affiliations Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America
⨯
Susanna Naggie

Contributed equally to this work with: Stacy M. Horner, Susanna Naggie

* E-mail: susanna.naggie@duke.edu

Affiliations Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Duke Clinical Research Institute, Durham, North Carolina, United States of America
⨯

Successes and Challenges on the Road to Cure Hepatitis C

Stacy M. Horner,
Susanna Naggie

Published: June 18, 2015
https://doi.org/10.1371/journal.ppat.1004854

About the Authors

Stacy M. Horner

Contributed equally to this work with: Stacy M. Horner, Susanna Naggie

Affiliations Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, United States of America, Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America

Susanna Naggie

Contributed equally to this work with: Stacy M. Horner, Susanna Naggie

* E-mail: susanna.naggie@duke.edu

Affiliations Department of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America, Duke Clinical Research Institute, Durham, North Carolina, United States of America

Competing Interests

I have read the journal's policy and have the following conflicts: SN has served as a scientific advisor to Gilead, AbbVie, Janssen, Bristol Meyers Squibb, Merck, and Boehringer Ingelheim. SN's institution has received research funds on her behalf from Gilead, AbbVie, Bristol Meyers Squibb, and Janssen. This does not alter our adherence to all PLOS policies on sharing data and materials.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Cirrhosis
Is the Subject Area "Cirrhosis" applicable to this article?

Thanks for your feedback.
Protease inhibitor therapy
Is the Subject Area "Protease inhibitor therapy" applicable to this article?

Thanks for your feedback.
Antiviral therapy
Is the Subject Area "Antiviral therapy" applicable to this article?

Thanks for your feedback.
Hepatitis C virus
Is the Subject Area "Hepatitis C virus" applicable to this article?

Thanks for your feedback.
Nucleotides
Is the Subject Area "Nucleotides" applicable to this article?

Thanks for your feedback.
Liver transplantation
Is the Subject Area "Liver transplantation" applicable to this article?

Thanks for your feedback.
Variant genotypes
Is the Subject Area "Variant genotypes" applicable to this article?

Thanks for your feedback.
Liver diseases
Is the Subject Area "Liver diseases" applicable to this article?

Thanks for your feedback.